Show all News

We are working to develop our technology and commercialise MSC-based pharmaceuticals – find out more about our day-to-day work.

Meet our Partners

We are a team is dedicated to the constant search for new biotechnology solutions. We create top-of-the-line stem cell-based pharmaceuticals for veterinary use and cooperate with prominent scientists in state-of-the-art laboratories in common pursuit of new technologies. We work together with the Wrocław Research Centre EIT+ – a Polish research and development organisation that develops new technologies. Our R&D centre draws on the resources and technological solutions found at EIT+ – this is where our GMP-compliant production facility is located. Faculty of Veterinary Medicine, Wrocław University of Environmental and Life Sciences – in cooperation with the university experts we are conducting a clinical field trial of our pharmaceutical. Together with the scientists of Ludwik Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences in Wrocław we are working on the advancement our products.
Our research scope also overlaps with the work of foreign institutes, including the Swedish Karolinska Institute (one of Sweden’s largest biomedical research centres) and with the German Fraunhofer Society for the Advancement of Applied Research (the largest European organisation specialising in applied research and its industrial applications).
Wrocław Research Centre EIT+ www.eitplus.pl/
Faculty of Veterinary Medicine, Wrocław University of Environmental and Life Sciences www.wet.up.wroc.pl/
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences  www.wet.up.wroc.pl/
Karolinska Institute in Sweden https://ki.se/en/startpage/
Fraunhofer Society for the Advancement of Applied Research in Germany https://www.fraunhofer.de/

Wrote about us

Puls Biznesu

Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...

Article

Forbes- Incredibles

Forbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...

Article

Investors’ Zone

According to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...

Article

Portal Wrocław

Gazeta Wrocławska wrote about us: “Bioceltix is ​​working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...

Article

Mam Startup – summary 2021

We create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...

Article